Exogenous administration of ADM and CGRP peptides or their gene delivery is a new preventive and therapeutic strategy for cardiovascular diseases such as hypertension, myocardial ischemia, heart failure, and renal failure [11, 59, 60]. This evidence concerns the gene ADM and hypertensive disorder.